Introduction
============

Non-steroidal anti-inflammatory drugs (NSAIDs) represent one of the most widely used classes of drugs ([@B48]). Despite they confer important clinical benefits across multiple indications, their use is associated with a wide array of adverse events involving different organs and systems (i.e., liver, kidney, cardiovascular system, skin, and gut). Those concerning the gastrointestinal tract are the most common and can cause both symptoms (dyspepsia, heartburn, and/or abdominal discomfort) and lesions (mucosal erosions and/or peptic ulcers, with their life-threatening ulcer complications of bleeding and perforation) ([@B39]; [@B62]). While NSAID-induced renal adverse events are well-known, those concerning cardiovascular system ([@B30]; [@B51]) have been appreciated only recently, after the rofecoxib fallout ([@B18]). Several investigations (like the LOGICA and the GIRANO studies) have shown that patients requiring NSAID therapy often display gastrointestinal or/and cardiovascular risk factors ([@B41]; [@B77]). Navigating through the different risk factors and balancing them with the potential benefits of NSAID therapy is clearly a difficult task.

Since in real life NSAID-associated gastrointestinal adverse events largely exceed the cardiovascular ones ([@B36]), these drugs are frequently co-prescribed with proton pump inhibitors (PPIs) to prevent NSAID-associated gastro-duodenal damage and symptoms. According to currently available guidelines ([@B76]; [@B63]) the co-administration of a gastroprotective compound (especially a PPI) in NSAID users, holding one or more gastrointestinal risk factors, has become the standard of care. Indeed, acid represents the *condition sine qua non* for development of peptic ulcer and related complications ([@B64]). However, since NSAID-enteropathy is not a pH-dependent phenomenon, PPIs do not exert any protective activity beyond the duodenum ([@B63]).

Already, in the early 80s, some studies ([@B7], [@B8]) showed that NSAID-associated gastrointestinal damage does extend also to the lower digestive tract. Later on, the clinical impact of lower gastrointestinal damage and complications was pointed out mainly by the first large prevention study with the synthetic prostaglandin, misoprostol (i.e., the MUCOSA trial) ([@B67]). In addition, the VIGOR trial (comparing rofecoxib with naproxen) reported that more than 40% of NSAID-related events occurred in the lower gastrointestinal tract ([@B35]). Over the past decade, the overall pattern of gastrointestinal events requiring hospitalization showed a reverse trend, with a decrease of events located in the upper gastrointestinal tract and a slight, albeit significant, increase in those concerning the small and large bowel ([@B37]).

The advent of new imaging techniques, such as video capsule endoscopy, has allowed to gain new insights into NSAID-induced intestinal damage, which appears to be site-dependent. The pattern of mucosal injury, which can be found in up to 75% of NSAID users ([@B29]; [@B45]), ranges from denuded areas (seen mainly in the proximal small bowel) to the so-called mucosal breaks (erosions and ulcers), observed in its distal part ([@B25]). Video capsule studies and/or fecal calprotectin measurement clearly showed that PPIs (like omeprazole) failed to prevent NSAID-associated intestinal injury both in healthy volunteers ([@B28], [@B27]; [@B45]) and patients ([@B29]). Recent experimental (for review see [@B9]) and clinical ([@B25]; [@B78]) evidence suggest that PPIs may actually aggravate NSAID injury in the small bowel.

The pathogenesis of small intestinal damage is still not completely understood. The synthesis of endogenous mucosal prostaglandins is inhibited by NSAID throughout the *entire* gastrointestinal tract. However, other important pathogenic factors, which contribute to damage, differ between the distal and proximal regions of the gut ([@B5]). Indeed, in the small bowel, the presence of bacteria and bile represent pivotal triggers of the mucosal damage ([@B40]; [@B60]; [@B9]).

Bile acids ([@B54]) and inhibition of endogenous mucosal prostanoids ([@B73]) are both implicated in the pathogenesis of NSAID-enteropathy. However, current interest is focused on NSAID-induced alterations in the gut microbiota, with consequent pathological activation of the downstream inflammatory pathways ([@B60]; [@B5]). Recent evidence (for review see [@B52]) points out the importance of nucleotide-binding oligomerization domain leucine rich repeat and pyrin domain-containing protein 3 (NLRP3) inflammasome in the interaction amongst gut microbiome, intestinal barrier and innate immune system, controlling in this way intestinal homeostasis. A recent study ([@B32]) suggested that NLRP3 inflammasome activation and associated IL-1β release play a key role in NSAID-induced enteropathy.

The pathogenic role of enteric bacteria is supported by a large experimental evidence (for review see [@B40]; [@B60]; [@B9]) showing that anti-microbials attenuate NSAID-enteropathy. In humans ([@B4]), metronidazole (an anti-microbial targeting most Gram-negative and Gram-positive anaerobic bacteria, [@B24]) was shown to reduce inflammation and blood loss in NSAID users, thus suggesting a therapeutic role for anti-microbials in this clinical setting. However, potential adverse effects as well as the risk of drug resistance, associated with the use of systemic anti-microbials, have so far precluded this interesting approach ([@B40]).

Rifaximin (4-deoxy-4′-methylpyrido\[1′,2′-1,2\]imidazo \[5,4-c\]rifamycin SV) is a semi-synthetic rifamycin derivative, retaining the broad spectrum of anti-bacterial activity shared by all the members of this drug class, but displaying a very low (\<1%) absorption from the gastrointestinal tract ([@B10]). Being poorly absorbed, it achieves intraluminal concentrations much higher than those needed to inhibit enteric bacteria. In addition, since it does not reach the systemic circulation, the risk of anti-microbial resistance of adverse effects is rather low ([@B65]). Originally approved for the treatment of gastrointestinal infections, the use of rifaximin has been subsequently extended to other organic (like diverticular disease and hepatic encephalopathy) and functional (such as irritable bowel syndrome and functional constipation) diseases of the digestive system ([@B65], [@B66]). Recently, the drug has been studied also in patients with inflammatory bowel disease ([@B26]; [@B57]).

Since rifaximin displays all the characteristics of an ideal antibiotic for targeting enterobacteria ([@B20]), its ability to prevent NSAID-induced intestinal damage has been evaluated in both experimental ([@B15]; [@B23]) and clinical ([@B61]) studies. In healthy volunteers indeed the number and severity of diclofenac-induced intestinal lesions (as evaluated by video capsule endoscopy) were reduced by co-administration of the drug ([@B61]).

To gain deep insights into the pathophysiology of NSAID-associated lesions and to unravel the mechanisms of rifaximin enteroprotective activity, we employed an animal model of diclofenac-enteropathy and studied the effects of this poorly absorbed antibiotic on mucosal lesions, inflammatory changes and underlying molecular patterns as well as alterations of gut microbiota induced by the NSAID. For this investigation, a recently developed formulation (designed to bypass the stomach and release the microgranules directly in the intestine) ([@B57]) was selected. It consists of microgranules of rifaximin, coated with a gastric acid-resistant polymer, which increases the intraluminal concentration of the drug, thus maximizing its therapeutic efficacy.

Materials and Methods {#s1}
=====================

Study Design
------------

The present study includes experiments based on morphological (histological evaluations), molecular (biochemical and protein expression assays), and microbiological (analysis of intestinal microbiota composition) techniques to examine the protective effects of rifaximin against NSAID-induced enteropathy in rats. Groups of animals were randomly assigned to treatments with drug vehicle, diclofenac, rifaximin or their combination. In all experiments, investigators performing laboratory analyses (which were made in duplicate) were blinded to the treatment protocol. The sample size (*n* = 10 per group) was based on the resource equation because the effects size was unknown ([@B14]). Numbers of animals for each experiment are detailed below and included in the figure legends.

Animals
-------

Experiments were performed on aged (40-week old) male Wistar rats (500--600 g). The animals were fed standard laboratory chow (Envigo, Udine, Italy) and tap water *ad libitum*, and were not employed for at least 1 week after their delivery to the laboratory. They were housed in solid-bottomed cages, equipped wire-mesh bottom inserts to prevent coprophagy and located in temperature-controlled rooms (at 22--24°C and 50--60% humidity) under a 12-h light cycle (06:00--18:00 h). Their care and handling were in accordance with the provisions of the European Community Council Directive 210/63/UE, recognized and adopted by the Italian Government. The experiments were approved by the Ethical Committee for Animal Experimentation of the University of Pisa and by the Italian Ministry of Health. The *in vivo* studies are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals ([@B34]).

Experimental Design
-------------------

Enteropathy was induced by diclofenac in accordance with the method previously developed in our laboratory ([@B22]). The dose of diclofenac was selected on the basis of our previous study, in which preliminary experiments were conducted to identify the timing and dose required to elicit lower gastrointestinal injury. In that study, the effects of increasing doses of diclofenac (2, 4, and 6 mg/kg), administered by gavage twice daily, were assessed at days 7 and 14 of treatment ([@B22]). The results showed that diclofenac, administered at 4 mg/kg BID, was able to produce the development of small intestinal damage after 14 days -- consistently with human data ([@B61]) -- without causing excessive mortality and, at the same time, remaining within the range of its inhibitory activity for both COX isoenzymes.

Rifaximin (suspended in 1% methylcellulose, 1 ml/rat) was administered as an extended intestinal release (E.I.R.) formulation (50 mg/kg BID) 1 h before diclofenac for 14 days. Due to the high frequency of treatments, intragastric administration of test drugs was performed in awake animals. Twenty-four hours after the last dose of test drugs, non-fasted rats were anesthetized with chloral hydrate. Blood samples were collected by cardiac puncture from each animal for hemoglobin measurement. Fecal pellets were collected directly from the sigmoid colon and stored at -80°C for calprotectin measurement. The whole gastrointestinal tract was excised and examined macroscopically. Samples of ileum were snap frozen in liquid nitrogen and stored at -80°C for subsequent analysis of myeloperoxidase (MPO), malondialdehyde (MDA), tumor necrosis factor (TNF) and interleukin-1β (IL-1β), as well as to assess: the expression of toll-like receptors-2 and -4 (TLR-2, TLR-4), and the myeloid-differentiation primary response gene 88 (MyD88), nuclear factor-κB (NF-κB) signaling and activation of caspase-1, and the expression of the tight junction protein occludin. Ileal samples were also processed for the evaluation of the main bacterial phyla abundance as well as the prevalence of the genus *Lactobacillus*, as reported below. Other portions of ileal tissue were fixed in 10% formalin for subsequent evaluation of microscopic damage.

The experimental groups were arranged as follows: **Group 1**: animals treated with vehicle (control, *n* = 10); **Group 2**: animals treated with diclofenac (*n* = 15); **Group 3**: animals treated with diclofenac plus rifaximin (*n* = 12); **Group 4**: animals treated with rifaximin alone (*n* = 12). Different numbers of animals for each group of treatment were employed to compensate for the different mortality rates affecting the groups of treatment (as observed also in our previous studies, [@B22]), in order to ensure at least 10 animals per group at the end of treatments.

Assessment of Intestinal Damage, Tissue Inflammation, and Tissue Cytokine Concentrations
----------------------------------------------------------------------------------------

Histology of the small bowel injury, tissue myeloperoxidase (MPO, as an index of intestinal wall infiltration of polymorphonuclear cells) and malondialdehyde (MDA, reflecting membrane lipid peroxidation) concentrations were measured according to previously adopted methods ([@B23]), detailed in [Supplementary Material](#SM2){ref-type="supplementary-material"}.

Tumor necrosis factor and Interleukin-1β (IL-1β) ileal concentrations were quantitated according to the methodology adopted in our laboratories ([@B23]; [@B53]). Tissue preparation is described in [Supplementary Material](#SM2){ref-type="supplementary-material"}.

Measurement of Fecal Calprotectin and Blood Hemoglobin Concentration
--------------------------------------------------------------------

Calprotectin, a calcium binding protein of neutrophil granulocytes that correlates well with neutrophil infiltration of the intestinal mucosa, was measured in fecal pellets, collected as reported above whereas hemoglobin analysis was performed on blood samples as previously described ([@B23]) (see [Supplementary Material](#SM2){ref-type="supplementary-material"}).

Western Blot Analyses
---------------------

Specimens of mucosa were excised from ileum, weighed and homogenized in lysis buffer, using a polytron homogenizer. Mucosal homogenates were spun by centrifugation at 15,000 *g* for 15 min at 4°C, and the resulting supernatants were then separated from pellets and stored at -80°C for subsequent quantification of TLR-2, TLR-4, MyD88, NF-κB p65 subunit, caspase-1 and occludin expression. The detailed procedure as well as primary and secondary antibodies employed are described in [Supplementary Material](#SM2){ref-type="supplementary-material"} and in the Supplementary Tables [S1, S2](#SM1){ref-type="supplementary-material"}.

Analysis of Bacterial Populations in Ileal Samples
--------------------------------------------------

Total DNA extracted from ileal tissues was analyzed for the mucosal-associated microbiota through 16S rDNA metagenomics. Metagenomic analysis was performed with MiSeq, Illumina platform at GenProbio SRL (Parma, Italy). The methodology employed to extract DNA from tissues as well the detailed procedure of 16S RNA gene amplification and MiSeq sequencing are detailed in [Supplementary Material](#SM2){ref-type="supplementary-material"}.

*In vitro* Assays on NLRP3 Inflammasome
---------------------------------------

The human monocyte cell line THP-1, a well-established model to study monocyte/macrophage functions, mechanisms, and signaling pathways ([@B13]), were cultured in RPMI 1640 media, supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 μg/ml streptomycin. Cells were plated in 24-well plates at a density of 5 × 10^5^ cells/well and treated with phorbol 12-myristate 13-acetate (0.5 μM). After 3 h, the medium was removed, fresh medium was added, and cells were incubated overnight (37°C, 5% CO~2~). Cells were primed with lipopolysaccharide (1 μg/ml, 4 h) to induce pro-IL-1β expression before treatment with nigericin (a standard NLRP3 inflammasome activator (10 μM, 1 h) ([@B47]), as described by [@B43]. Lipopolysaccharide-primed cells were treated for 2 h with rifaximin (25, 50, or 100 μM) before the addition of nigericin. Thereafter, lipopolysaccharide-primed and nigericin-treated cells (in the presence or absence of rifaximin) were incubated for a total of 5 h before the collection of supernatants and cell lysates for western blot assay of caspase-1 and measurement of IL-1β concentrations, as described in [Supplementary Material](#SM2){ref-type="supplementary-material"}.

Statistical Analysis
--------------------

Results are presented as mean ± standard error of mean (SEM). The statistical significance of data was evaluated by one-way analysis of variance (ANOVA) followed by *post hoc* analysis by Student--Newman--Keuls test, and *p*-values less than 0.05 were considered significant. All statistical calculations were performed using GraphPad Prism^TM^ 3.0 software (GraphPad, San Diego, CA, United States).

Results
=======

Macroscopic Appearance of the Intestine
---------------------------------------

A quantitative evaluation of the macroscopic injury elicited by diclofenac was difficult to perform, due to the large mucosal surface. However, diaphragm-like strictures and multiple ulcerative lesions, both hallmark of NSAID-enteropathy, were clearly present in rats given the NSAID, a picture not seen in animals treated with diclofenac plus rifaximin or rifaximin alone. Representative images, showing the macroscopic appearance of small intestine in the different treatment groups, are displayed in Supplementary Figure [1](#SM3){ref-type="supplementary-material"}.

Microscopic Assessment of Intestinal Damage
-------------------------------------------

In the ileum from control animals, microscopic examination did not reveal any type of lesion as was the case for rats treated with rifaximin alone. Administration of diclofenac was associated with the appearance of types 1, 2, and 3 lesions in the ileum (Figure [1](#F1){ref-type="fig"}). In animals treated with diclofenac+rifaximin, all types of NSAID-induced lesions were significantly decreased, as compared with rats treated with diclofenac alone (Figure [1](#F1){ref-type="fig"}).

![Histological analysis of damage in the ileum of rats treated with vehicle (Control), diclofenac (DIC, 4 mg/kg BID), diclofenac plus rifaximin (DIC+RIF, 50 mg/kg BID), or rifaximin (RIF) for 14 days. Representative pictures showing the microscopic appearance of ileal mucosa from control animals **(A)**, as well as type 1 **(B)**, type 2 **(C)** or type 3 **(D)** lesions, observed in animals treated with DIC. Effects of treatments on type 1 **(E)**, type 2 **(F)**, or type 3 **(G)** lesions. Each column represents the mean ± SEM obtained from 10 animals. ^∗^*p* \< 0.05, significant difference versus Control; ^a^*p* \< 0.05, significant difference vs. diclofenac alone.](fphar-09-01340-g001){#F1}

Hemoglobin Blood Levels
-----------------------

Mean hemoglobin concentration in the blood of control rats was 16.0 g/dL. A similar figure was obtained in animals given rifaximin alone. Compared to controls, diclofenac treatment induced a significant blood loss, as mirrored by the drop of blood hemoglobin concentration. This decrease was blunted by co-administration of rifaximin (Figure [2A](#F2){ref-type="fig"}). However, the hemoglobin levels of animals treated with both diclofenac and rifaximin did not achieve those of control animals, since upper gastrointestinal bleeding was likely not prevented by the antibiotic.

![Effects of vehicle (Control), diclofenac (DIC, 4 mg/kg BID), diclofenac plus rifaximin (DIC+RIF, 50 mg/kg BID), or rifaximin (RIF) for 14 days on blood hemoglobin **(A)** or fecal calprotectin levels **(B)**. Each column represents the mean ± SEM obtained from 10 animals. ^∗^*p* \< 0.05, significant difference versus Control; ^a^*p* \< 0.05, significant difference versus diclofenac alone.](fphar-09-01340-g002){#F2}

Fecal Calprotectin Levels
-------------------------

The concentration of calprotectin in feces collected from control animals was 2.03 ng/mg feces. Animals treated with diclofenac displayed higher concentrations of fecal calprotectin (3.48 ng/mg feces) (Figure [2B](#F2){ref-type="fig"}). In rats treated with diclofenac+rifaximin, the levels of calprotectin were significantly reduced, approaching control values. Animals treated with rifaximin alone displayed levels of fecal calprotectin not significantly different from those observed in control animals.

Tissue MPO Levels
-----------------

Myeloperoxidase levels in ileal specimens taken from control rats accounted for 5.98 ng/mg tissue (Figure [3A](#F3){ref-type="fig"}) and were not modified by rifaximin alone. In animals treated with diclofenac, MPO levels were significantly increased (23.57 ng/mg tissue) (Figure [3A](#F3){ref-type="fig"}). In the ileum of rats treated with diclofenac+rifaximin, MPO levels were lower as compared with diclofenac alone and reverted back to the values of control animals.

![Effects of vehicle (Control), diclofenac (DIC, 4 mg/kg BID), diclofenac plus rifaximin (DIC+RIF, 50 mg/kg BID), or rifaximin (RIF) for 14 days on myeloperoxidase (MPO) **(A)**, malondialdehyde (MDA) **(B)**, tumor necrosis factor (TNF) **(C)**, or interleukin-1β (IL-1β) **(D)** in the ileum. Each column represents the mean ± SEM obtained from 10 animals. ^∗^*p* \< 0.05, significant difference versus Control; ^a^*p* \< 0.05, significant difference versus diclofenac alone.](fphar-09-01340-g003){#F3}

Tissue MDA Levels
-----------------

In the ileum of control rats, the MDA concentration was 24.06 nmol/mg of tissue and, again, was not changed by administration of rifaximin. Animals treated with diclofenac displayed a significant increment of ileal MDA levels (59.1 nmol/mg of tissue) (Figure [3B](#F3){ref-type="fig"}), which were significantly reduced by co-administration of rifaximin.

Tissue TNF Levels
-----------------

TNF levels in ileum from control rats accounted for 2.65 pg/mg of tissue, and were not modified by treatment with rifaximin alone. The administration of diclofenac was associated with a significant increase in TNF concentration (Figure [3C](#F3){ref-type="fig"}). Compared with rats given diclofenac alone, animals treated with diclofenac+rifaximin showed a significant decrease in tissue TNF concentrations. However, the observed values were still higher (albeit not significantly different) than those observed in control animals (Figure [3C](#F3){ref-type="fig"}).

Tissue IL-1β Levels
-------------------

In control rats, IL-1β levels accounted for 13.2 pg/mg tissue and were not affected by treatment with rifaximin alone (Figure [3D](#F3){ref-type="fig"}). Rats treated with diclofenac displayed a significant increase in tissue IL-1β levels, as compared with control animals. Under these conditions, the concomitant administration of rifaximin was associated with a normalization of ileal levels of the cytokine (Figure [3D](#F3){ref-type="fig"}).

Expression of TLR-2, TLR-4, MyD88, NF-κB p65 Subunit and Caspase-1
------------------------------------------------------------------

The expression of TLR-2 in small intestinal mucosa was enhanced in animals treated with diclofenac, as compared to controls (Figure [4A](#F4){ref-type="fig"}). Under these conditions, the co-administration with rifaximin was associated with a significant decrease in the receptor expression, while rifaximin administered alone had no significant effect (Figure [4A](#F4){ref-type="fig"}).

![Western blot analysis of toll-like receptor-2 (TLR-2) **(A)**, toll-like receptor-4 (TLR-4) **(B)**, myeloid-differentiation primary response gene 88 (MyD88) **(C)**, activated nuclear factor-κB (p65) **(D)**, pro-caspase-1 **(E)**, and caspase-1 (p20) **(F)** in the ileum of rats treated with vehicle (Control), diclofenac (DIC, 4 mg/kg BID), diclofenac plus rifaximin (DIC+RIF, 50 mg/kg BID), or rifaximin (RIF) for 14 days. Each column represents the mean ± SEM obtained from 10 animals. ^∗^*p* \< 0.05, significant difference versus Control; ^a^*p* \< 0.05, significant difference versus diclofenac alone. Note that the beta actin signals in **(A,D)** result from stripping and re-probing the same membrane, where TLR-2- and p65 proteins have been detected.](fphar-09-01340-g004){#F4}

Rats treated with diclofenac displayed also an increased expression of TLR-4 in ileal mucosa. The administration of diclofenac plus rifaximin elicited a significant reduction of TLR-4 expression (Figure [4B](#F4){ref-type="fig"}), and again rifaximin alone did not modify it.

Treatment with diclofenac resulted in a significant increment of MyD88 expression in the ileal mucosa (Figure [4C](#F4){ref-type="fig"}). The administration of rifaximin prevented the diclofenac-induced MyD88 higher expression. In rats treated with rifaximin alone, the levels of MyD88 expression were similar to those detected in control animals (Figure [4C](#F4){ref-type="fig"}).

The expression of the p65 subunit was increased in the ileum from rats treated with diclofenac, in comparison with control animals (Figure [4D](#F4){ref-type="fig"}). Under these experimental conditions, co-treatment with rifaximin counterbalanced the higher expression of p65, while rifaximin administration to control animals did not affect the pattern of p65 expression (Figure [4D](#F4){ref-type="fig"}).

Expression of pro-caspase-1 (50 KD) in ileal tissue did not differ among the experimental groups (Figure [4E](#F4){ref-type="fig"}). Cleaved caspase-1 (p20, an autoprocessed fragment of caspase-1) expression in ileal tissues from rats treated with diclofenac was significantly increased, in comparison with controls (Figure [4F](#F4){ref-type="fig"}). The concomitant administration of rifaximin prevented this increase, while rifaximin administered alone did not exert any significant effect (Figure [4F](#F4){ref-type="fig"}).

Expression of Occludin
----------------------

Western blot assay revealed a well-detectable expression of occludin in the ileal mucosa from control animals (Figure [5](#F5){ref-type="fig"}). By contrast, in rats with diclofenac-induced enteropathy the expression of occludin was markedly reduced. However, the administration of rifaximin to animals with diclofenac-induced enteropathy restored the occludin expression to values similar to those detected in control animals. The administration of rifaximin to normal rats did not significantly change occludin expression (Figure [5](#F5){ref-type="fig"}).

![Western blot analysis of occludin in the ileum of rats treated with vehicle (Control), diclofenac (DIC, 4 mg/kg BID), diclofenac plus rifaximin (DIC+RIF, 50 mg/kg BID), or rifaximin (RIF) for 14 days. Each column represents the mean ± SEM obtained from 10 animals. ^∗^*p* \< 0.05, significant difference versus Control; ^a^*p* \< 0.05, significant difference versus diclofenac alone.](fphar-09-01340-g005){#F5}

Analysis of Bacterial Populations
---------------------------------

In control animals, the relative abundance of *Proteobacteria, Firmicutes, Bacteroidetes*, and *Actinobacteria* was 4.8, 84.6, 6.8, and 0.6%, respectively. Treatment with diclofenac was associated with an increase in the relative abundance of *Proteobacteria* and *Bacteroidetes* and a decrease in *Firmicutes* (Figure [6A](#F6){ref-type="fig"}). The administration of rifaximin to diclofenac-treated rats partially counterbalanced these changes, while rifaximin alone did not exert significant effects (Figure [6A](#F6){ref-type="fig"}). No relevant changes were observed in the relative abundance of other phyla amongst the different groups (*Data not shown*). When the genus *Lactobacillu*s was specifically analyzed, a substantial decrease was found after diclofenac treatment. Rifaximin partially counterbalanced the NSAID-induced decrease, while it did not affect the relative abundance of *Lactobacillus*, when given alone (Figure [6B](#F6){ref-type="fig"}). No substantial differences were observed in the prevalence of other main bacterial species among the various groups (*Data not shown*).

![**(A)** Relative abundance of *Proteobacteria, Firmicutes, Bacteroidetes*, and Actinobacteria and **(B)** prevalence of *Lactobacillus* spp. in the ileum of rats treated with vehicle (Control), diclofenac (DIC, 4 mg/kg BID), diclofenac plus rifaximin (DIC+RIF, 50 mg/kg BID), or rifaximin (RIF) for 14 days. Each column represents the mean ± SEM obtained from 10 animals. ^∗^*p* \< 0.05, significant difference versus Control; ^a^*p* \< 0.05, significant difference versus diclofenac alone.](fphar-09-01340-g006){#F6}

IL-1β Release and Caspase-1 Activation in THP-1 Cells
-----------------------------------------------------

Incubation with nigericin stimulated IL-1β release in lipopolysaccharide-primed THP-1 cells (Figure [7A](#F7){ref-type="fig"}). Treatment with rifaximin significantly reduced nigericin-induced IL-1β release in a concentration-dependent fashion (Figure [7A](#F7){ref-type="fig"}).

![Lipopolysaccharide-primed THP-1 cells treated with rifaximin (RIF, 25, 50, or 100 μM) before the addition of nigericin (10 μM). **(A)** Effect of rifaximin (RIF) on interleukin-1β (IL-1β) release in cell supernatants. **(B)** Effect of rifaximin (RIF) on caspase-1 p20 expression in cell supernatants as well as on pro-caspase-1 expression in cell lysates. Each column represents the mean ± SEM value obtained from four separate experiments. ^∗^*p* \< 0.05, significant difference versus cells treated with nigericin alone.](fphar-09-01340-g007){#F7}

THP-1 supernatants were assayed for cleavage of caspase-1. Nigericin induced the cleavage of pro-caspase-1 into caspase-1 p20) (Figure [7B](#F7){ref-type="fig"}). The incubation of THP-1 cells with rifaximin resulted in a decreased activation of caspase-1. By contrast, rifaximin did not affect the expression of pro-caspase-1 in cell lysates (Figure [7B](#F7){ref-type="fig"}).

Discussion
==========

Results of the present investigation clearly show that rifaximin administration together with diclofenac protects the small bowel from the damaging effect of this NSAID, in line with the findings obtained in experimental animals with indomethacin ([@B15]; [@B23]) and in healthy volunteers with diclofenac ([@B61]).

The Enteropathy Model
---------------------

The experimental model, set up in our laboratory, was developed to mimic clinical practice with NSAID *chronic* administration in humans. Since elderly patients are more prone to develop enteropathy ([@B38]; [@B80]), likely as consequence of an aging gut ([@B59]) and/or co-morbidities and co-therapies ([@B81]), the present study was conducted on 40-week old rats. Most experimental studies did use single, high doses of NSAIDs (mainly indomethacin) to induce small bowel damage. Under these experimental conditions, the mucosal injury is usually represented by a number of bleeding lesions, affecting deeply the intestinal wall ([@B1]; [@B31]; [@B83]). This lesion pattern does not mirror at all the one found during endoscopic investigations in long-term NSAID users ([@B29]; [@B45]; [@B25]). In our experimental conditions, however, diclofenac-induced small bowel damage consisted of diaphragm-like strictures and multiple erosive lesions (along with anemia), similarly to those found in patients receiving long-term NSAID treatment ([@B45]).

Pathophysiology of NSAID-Associated Intestinal Lesions
------------------------------------------------------

More than 25 years ago, [@B8], [@B4]) first showed that inflammation and blood loss (evaluated by means of fecal excretion of ^111^In-labeled neutrophils and of ^51^Cr-labeled red cells, respectively) are significantly increased in patients with NSAID-enteropathy, the two parameters being correlated to each other. Both inflammation and blood loss were significantly reduced by 2--12 week treatment with metronidazole (800 mg/day) ([@B4]). These findings suggested that NSAID-driven intestinal damage is associated with significant mucosal inflammation, which could be easily detected by the increase in fecal calprotectin ([@B75]; [@B45]; [@B27]), and that the main neutrophil chemo-attractants may be metronidazole-sensitive bacteria.

Along with the intestinal lesions, in our experimental model, inflammation and blood loss paralleled the findings observed in humans. Indeed, MPO, TNF, and IL-1β tissue concentrations as well as fecal calprotectin were significantly increased in rats after diclofenac treatment. In addition, oxidative stress (evaluated as lipid peroxidation, [@B33]) also increased in the intestinal mucosa as a consequence of tissue damage. Co-administration of rifaximin with diclofenac counterbalanced all these changes whereas the antibiotic alone did not affect any of these parameters.

Several studies have shown that almost all non-selective NSAIDs induce an early (within 24 h of ingestion) increase of intestinal permeability in humans, an effect that persists after chronic administration ([@B17]; [@B6]). Impairment of enteric mucosal barrier represents the *primum movens* of a series of pathophysiologic events, leading to mucosal damage. Indeed, the disrupted intercellular tight-junctions (TJs) facilitate the entrance and action of bacteria or bacterial antigens (as well as other luminal factors), which induce a higher expression and enhanced release of pro-inflammatory cytokines from the intestinal epithelium. Occludin, a 65-kDa tetraspan integral membrane protein, contributes to TJ stabilization and optimal barrier function, and its dysregulation is an established pathophysiologic hallmark of clinical conditions (like NSAID-enteropathy) with underlying alterations of intestinal permeability ([@B21]; [@B16]). In this connection, we found a remarkable down-regulation of this TJ protein in the ileal tissue of diclofenac-treated animals. This finding is in line with the decrease in occludin expression induced by indomethacin in Caco-2 (human epithelial colorectal adenocarcinoma) cell monolayers ([@B11]).

Disruption of the intestinal TJ barrier is an important pathogenic mechanism leading to increased epithelial penetration of luminal noxious molecules, with consequent activation of the mucosal immune system and subsequent development of intestinal inflammation ([@B70]). The release of pro-inflammatory cytokines causes further disturbances of the intestinal barrier, thus amplifying immune activation and the inflammatory reaction ([@B2]). In our experimental model, together with increased ileal concentrations of TNF and IL-1β, we observed a higher expression of both TLR-4 and TLR-2. In an *acute* model of NSAID-enteropathy, [@B79] reported up-regulation of TLR-4 suggesting the involvement of Gram-negative bacteria in the pathogenesis of mucosal inflammation and intestinal lesions. Our findings, showing TLR-2 higher expression, suggest a role *also* for Gram-positive microorganisms. Indeed, TLR-4 was found to be a receptor for LPS (major component of the outer membrane of Gram-negative bacteria) while TLR-2 binds peptidoglycan and lipoteichoic acid (major cell wall components of Gram-positive bacteria) ([@B72]; [@B49]). Stimulation of all TLRs activates MyD88-dependent Nuclear Factor-κB (NF-κB) signaling, which plays a critical role for an effective immune response ([@B49]), a pathway observed under our experimental conditions. However, while TLR-2-mediated NF-κB activation is fully MyD88-dependent, LPS activates both MyD88-dependent and independent pathways ([@B74]).

TLR higher expression, along with downstream activation of the NF-κB pathway, suggests the involvement of the NLRP3 inflammasome in the pathogenesis of NSAID-associated intestinal inflammation. Indeed, consistent with this hypothesis, in diclofenac-treated animals, we found an increased cleavage of pro-caspase 1 into caspase-1, followed by elevated ileal concentrations of IL-1β, a well-established pattern of *canonical* NLRP3 inflammasome activation ([@B52]). In line with these findings, [@B32] observed -- in an *acute* model of indomethacin-induced enteropathy -- an increase in mRNA expression of the NLRP3 inflammasome, together with an increase in tissue levels of caspase-1 and IL-1β.

Metagenomic analysis revealed that diclofenac administration induced an increase in the relative abundance of Proteobacteria and Bacteroidetes. Recent investigations reported a marked increase in Proteobacteria in naproxen-treated ([@B71]) and indomethacin-treated ([@B23]) rats, and suggested that these microbial changes might contribute to NSAID-induced intestinal damage. The marked decrease in the *Lactobacillus* genus found in diclofenac-treated animals parallels its almost complete depletion observed in elderly NSAID users ([@B46]).

In the healthy bowel, commensal non-pathogenic bacteria interact with the host mucosa, co-regulating the function of mucosal barrier. In this context, *Lactobacillus* deficiency may contribute to the development of NSAID-enteropathy. Indeed, these probiotic bacteria exert a protective effect on the intestinal barrier and reduce intestinal permeability ([@B50]; [@B42]), and several experimental and human studies (for review see [@B71]) have shown their ability to prevent NSAID-induced small bowel lesions.

Mechanisms of Rifaximin Mucosal Protection
------------------------------------------

The entero-protective effect of rifaximin, observed in this study, was associated with a decrease in tissue inflammation (as reflected by the reduced MPO, TNF, and IL-1β mucosal concentrations) and oxidative stress (mirrored by lowed MDA tissue levels). Along the same lines, diclofenac-induced blood loss and increased fecal calprotectin concentrations were significantly reduced by rifaximin. These findings are in line with the results previously obtained in our laboratories in the setting of indomethacin-enteropathy ([@B23]).

New findings in the present investigation concern the reversal by rifaximin of the TLR-2 and TLR-4 higher expression and downstream pro-inflammatory signaling, accompanied by complete recovery of the TJ protein occludin, the expression of which was severely impaired by diclofenac administration. Rifaximin also partially reverted the diclofenac-induced shift of bacterial phyla toward an increase in *Proteobacteria* and *Bacteroidetes* abundance. Most importantly, the drug also increased the proportion of Lactobacilli, a genus depleted by the NSAID.

The nature of the anti-inflammatory activity of rifaximin could be the consequence of its anti-microbial properties (and therefore indirect) or intrinsic to the pharmacologic properties of the drug (i.e., a direct one). Drugs belonging to the rifamycin class exert anti-inflammatory activity, which seems to be independent from the anti-microbial properties. Rifamycins indeed inhibit human neutrophil functions ([@B68], [@B69]) and intra-articular rifamycin SV was shown to be effective in patients with chronic arthritides, like juvenile rheumatoid arthritis and ankylosing spondylitis ([@B12]).

Some studies, including our own, have shown the rifaximin ability of inhibiting inflammatory cytokine release in the intestinal mucosa, induced by chronic stress ([@B82]) or NSAID administration ([@B23]) in rats. In addition, the drug reduced cytokine production from LPS-activated THP-1 monocytes *in vitro* ([@B58]), thus suggesting an *intrinsic* anti-inflammatory activity. This last investigation, however, did not provide any mechanistic explanation for the anti-inflammatory effect of rifaximin. Since we (this study) and others ([@B32]) have shown that NSAID-associated intestinal mucosal inflammation is mediated via NLRP3 inflammasome activation, an effect counterbalanced by rifaximin administration, we hypothesized that the anti-inflammatory activity of this antibiotic could rely on a modulation of NLRP3 inflammasome activity. Therefore, rifaximin was tested in an *in vitro* cell system (LPS-primed THP-1 cells stimulated by nigericin) for its ability to modulate NLRP3 inflammasome pathway. In accordance with our hypothesis, the drug reduced IL-1β production in a dose-dependent fashion, this effect being associated with inhibition of the up-stream caspase-1 activation. This original observation provides compelling evidence for an *intrinsic* anti-inflammatory activity of rifaximin.

Rifaximin for Prevention of NSAID-Enteropathy in Clinical Practice
------------------------------------------------------------------

Recent evidence is consistent with the idea that -- besides non-anti-microbial activities (e.g., anti-inflammatory action) -- rifaximin displays also "eubiotic" properties. In patients with inflammatory conditions of the digestive system (inflammatory bowel disease, colonic diverticular disease or hepatic encephalopathy), this antibiotic -- conversely from systemic anti-microbials -- did not change the overall human colonic microbiota, but actually increased the relative abundance of Bifidobacteria and Lactobacilli ([@B44]; [@B82]; [@B56]).

NSAID therapy is often required in long-term, especially in chronic inflammatory conditions. As a consequence, also prevention of NSAID gastrointestinal injury needs to be long-term and should be accomplished with effective and safe drugs. Rifaximin proved to be extremely safe. Indeed, its minimal, if any, systemic absorption translates into an adverse event profile, overlapping that of placebo, even after 6-month continuous administration ([@B3]). In addition to the lack of emergence of pathogenic bacteria, occurrence of opportunistic infections, and alteration of the overall microbiota, no clinically relevant changes in bacterial sensitivity to other antibiotic classes have been reported ([@B19]; [@B55]).

*In summary*, co-administration of rifaximin with diclofenac prevents NSAID-induced small bowel damage in rats. These results and those of a recent proof-of-concept study in humans ([@B61]) suggest that targeting enteric bacteria and mucosal inflammation by a poorly absorbed antibiotic, such as rifaximin, is an attractive therapeutic avenue for the prevention of NSAID-enteropathy ([@B60]).
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